Low-T Lawsuit Update (MDL 2545): FDA Weighs Data on Testosterone Drugs and Heart Attack Risk
The U.S. Food and Drug Administration (FDA) has called a special advisory committee meeting to discuss the results of two trials that demonstrated an increased risk of heart attack in men using testosterone replacement drugs.
The FDA called the meeting after it required new label changes on all testosterone replacement therapies to warn consumers of blood clot risks. The meeting will take place on September 17, 2014 and will include the FDA’s Bone, Reproductive & Urologic Drugs Panel and the Drug Safety & Risk Management Committee.
The advisory committees will review two new studies involving testosterone products in addition to other materials from the FDA’s ongoing investigation into the Low-T products. The focus of the meeting will be to weigh the heart attack risks of heart attack in testosterone replacement drugs against any benefit of the drugs.
The current testosterone market totals $1.6 billion and is expected to grow to $5 billion by 2017. These monetary figures are partly attributed to the aggressive marketing tactics of the testosterone drug manufacturers. Low-T manufacturers are now facing a multitude of lawsuits after the Judicial Panel on Multidistrict Litigation entered an order consolidating all claims filed in federal court over alleged injuries involving the testosterone products into a Multidistrict Litigation (MDL 2545) pending in the Northern District of Illinois. There are 156 cases currently pending in the consolidated MDL 2545 and the number of cases filed continues to grow.
If you or a loved one has suffered injuries after using testosterone products, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.
The choice of a lawyer is an important decision and should not be based solely on advertisements.